Screening for bladder cancer at the Du Pont Chambers Works: initial findings.
The following data have been abstracted on all persons ever screened for bladder cancer and on all persons known to have developed bladder cancer among the Chambers Works employees, regardless of whether they had been screened: complete work histories, including dates of employment by job title and location for the duration of employment by Du Pont; medical histories, including the dates and results of every urinary cytological reading and urinary blood test, and the dates and type of every physical examination; and vital status information, including data from death certificates. For each bladder cancer case, detailed clinical histories were abstracted to provide information concerning signs or symptoms of bladder cancer, procedures performed, findings, and recommendations. Pathological information includes type, grade, stage, evidence of multicentricity, metastatic sites, and second primary sites of malignancy. Data are being edited and subjected to preliminary analysis.
D015081:2-Naphthylamine / Q000633:toxicity*; D001560:Benzidines / Q000633:toxicity; D002617:Chemical Industry; D006801:Humans; D008403:Mass Screening / Q000379:methods; D009281:Naphthalenes / Q000633:toxicity*; D009515:New Jersey; D009784:Occupational Diseases / Q000139:chemically induced* / Q000453:epidemiology; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000453:epidemiology
D001560:Benzidines; D009281:Naphthalenes; C029876:benzidine; D015081:2-Naphthylamine